Recent Posts
Anaveon presents compelling data from the Phase I/II study of ANV419 during the AACR Annual Meeting 2022April 11, 2022
Anaveon to present first clinical data from the Phase I/II study of ANV419 at the AACR Annual Meeting 2022March 9, 2022
Anaveon to raise CHF 110 million in oversubscribed Series B financingDecember 16, 2021